Company: IMRX
Filing Date: 2025-09-25
Form Type: 424B5
Source: 0001104659-25-093438
Chunk: 15

Company: Immuneering Corp
Filing Date: 2025-09-25
Form: 424B5
Chunk 15
---
 our management will have broad discretion in the application of the net proceeds. Pending the uses described above, we plan to invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.

<div align='center'>S-11</div>

TABLE OF CONTENTS

### DIVIDEND POLICY
We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain all available funds and future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, potential future debt instruments may materially restrict our ability to pay dividends on our common stock. Payment of future cash dividends, if any, will be at the discretion of the board of directors after taking into account various factors, including our financial condition, operating results, current and anticipated cash needs, the requirements of current or then-existing debt instruments and other factors the board of directors deems relevant.

<div align='center'>S-12</div>

TABLE OF CONTENTS

DILUTION If you invest in our securities, your interest will be diluted to the extent of the difference between the price per share you pay in this offering and the net tangible book value per share of our common stock immediately after this offering and the concurrent private placement. The net tangible book value of shares of our common stock as of June 30, 2025 was $18.4 million, or $0.51 per share, based upon 35,987,306 shares of our Class A common stock and no shares of our Class B common stock outstanding as of June 30, 2025. Net tangible book value per share is equal to our total tangible assets, less our total liabilities, divided by the total number of shares outstanding as of June 30, 2025. After giving effect to the sale of 18,959,914 shares of Class A common stock in this offering and 2,708,559 shares of Class A common stock in the concurrent private placement, after deducting the underwriting discounts and commissions and estimated offering expenses and private placement fees payable by us, our as adjusted net tangible book value per share of common stock as of June 30, 2025 would have been $205.8 million, or $3.57 per share. This represents an immediate increase in net tangible book value of $3.06 per share to our existing holders